NPC in Chain Drug Review: The Long-term Health Benefits of Biopharmaceuticals
In his latest column for Chain Drug Review, National Pharmaceutical Council (NPC) President and Chief Executive Officer Dan Leonard highlights the importance of taking a holistic view of health care spending, rather than zeroing in on a single aspect of the health care system. The implications, he notes, are that “focusing only on the costs of a few innovative treatments doesn’t enable us to take a step back and see the bigger picture,” and that could have significant implications for health policy decisions.
During the last few months, we’ve seen an intense focus on the cost of medicines, including a Senate hearing featuring seven biopharmaceutical executives. But the conversations about medicines, like the Senate hearing, have been narrowly focused on list and net prices or on specific medicines.
In his latest column for Chain Drug Review, National Pharmaceutical Council (NPC) President and Chief Executive Officer Dan Leonard highlights the importance of taking a holistic view of health care spending, rather than zeroing in on a single aspect of the health care system. The implications, he notes, are that “focusing only on the costs of a few innovative treatments doesn’t enable us to take a step back and see the bigger picture,” and that could have significant implications for health policy decisions.
>> Read Mr. Leonard’s column in Chain Drug Review to learn more.